Actinium Pharmaceuticals’ (ATNM) Buy Rating Reiterated at HC Wainwright

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $4.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 223.89% from the company’s previous close.

Separately, Stephens reiterated an “overweight” rating and issued a $5.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Actinium Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $7.40.

Actinium Pharmaceuticals Stock Down 5.0 %

Actinium Pharmaceuticals stock traded down $0.07 during mid-day trading on Tuesday, reaching $1.24. 138,635 shares of the company’s stock traded hands, compared to its average volume of 179,515. Actinium Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $10.24. The company has a market cap of $38.53 million, a price-to-earnings ratio of -0.89 and a beta of 0.10. The stock has a 50 day moving average of $1.21 and a two-hundred day moving average of $1.47.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in shares of Actinium Pharmaceuticals during the third quarter valued at approximately $268,000. JPMorgan Chase & Co. boosted its holdings in Actinium Pharmaceuticals by 804.5% during the 4th quarter. JPMorgan Chase & Co. now owns 123,831 shares of the company’s stock valued at $156,000 after acquiring an additional 110,141 shares during the period. Deutsche Bank AG boosted its position in Actinium Pharmaceuticals by 413.6% in the 4th quarter. Deutsche Bank AG now owns 123,134 shares of the company’s stock valued at $155,000 after buying an additional 99,158 shares during the period. Renaissance Technologies LLC grew its stake in Actinium Pharmaceuticals by 49.9% in the 4th quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock worth $240,000 after acquiring an additional 63,400 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in shares of Actinium Pharmaceuticals during the third quarter worth approximately $112,000. 27.50% of the stock is currently owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).